Roberts, Glore & Co’s AbbVie ABBV Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $6.46M | Sell |
29,699
-310
| -1% | -$68.8K | 1.77% | 10 |
|
|
2025
Q4 | $6.86M | Sell |
30,009
-494
| -2% | -$113K | 1.83% | 10 |
|
|
2025
Q3 | $7.06M | Buy |
30,503
+26
| +0.1% | +$5.29K | 1.93% | 11 |
|
|
2025
Q2 | $5.66M | Buy |
30,477
+1,571
| +5% | +$292K | 1.65% | 12 |
|
|
2025
Q1 | $6.06M | Sell |
28,906
-984
| -3% | -$191K | 1.85% | 10 |
|
|
2024
Q4 | $5.31M | Sell |
29,890
-552
| -2% | -$101K | 1.58% | 13 |
|
|
2024
Q3 | $6.01M | Sell |
30,442
-2,408
| -7% | -$449K | 1.74% | 11 |
|
|
2024
Q2 | $5.63M | Sell |
32,850
-734
| -2% | -$122K | 1.7% | 11 |
|
|
2024
Q1 | $6.12M | Sell |
33,584
-5,913
| -15% | -$1.02M | 1.83% | 11 |
|
|
2023
Q4 | $6.12M | Sell |
39,497
-6,017
| -13% | -$877K | 1.91% | 10 |
|
|
2023
Q3 | $6.78M | Sell |
45,514
-631
| -1% | -$92.6K | 2.24% | 9 |
|
|
2023
Q2 | $6.22M | Sell |
46,145
-1,478
| -3% | -$217K | 1.99% | 9 |
|
|
2023
Q1 | $7.59M | Sell |
47,623
-761
| -2% | -$116K | 2.54% | 7 |
|
|
2022
Q4 | $7.82M | Sell |
48,384
-5,275
| -10% | -$809K | 2.71% | 7 |
|
|
2022
Q3 | $7.2M | Sell |
53,659
-1,744
| -3% | -$250K | 2.57% | 7 |
|
|
2022
Q2 | $8.49M | Sell |
55,403
-4,099
| -7% | -$626K | 2.82% | 6 |
|
|
2022
Q1 | $9.65M | Sell |
59,502
-79,979
| -57% | -$11.6M | 2.78% | 6 |
|
|
2021
Q4 | $18.9M | Buy |
139,481
+66,929
| +92% | +$7.91M | 4.97% | 4 |
|
|
2021
Q3 | $7.83M | Sell |
72,552
-1,228
| -2% | -$140K | 2.38% | 8 |
|
|
2021
Q2 | $8.31M | Sell |
73,780
-2,252
| -3% | -$254K | 2.49% | 8 |
|
|
2021
Q1 | $8.23M | Sell |
76,032
-2,621
| -3% | -$280K | 2.57% | 6 |
|
|
2020
Q4 | $8.43M | Sell |
78,653
-64
| -0.1% | -$6.15K | 2.75% | 6 |
|
|
2020
Q3 | $6.89M | Buy |
78,717
+7
| +0% | +$659 | 2.46% | 7 |
|
|
2020
Q2 | $7.73M | Sell |
78,710
-3,734
| -5% | -$329K | 3.02% | 6 |
|
|
2020
Q1 | $6.28M | Sell |
82,444
-66
| -0.1% | -$5.62K | 2.68% | 6 |
|
|
2019
Q4 | $7.3M | Buy |
82,510
+57,378
| +228% | +$4.76M | 2.79% | 6 |
|
|
2019
Q3 | $1.9M | Sell |
25,132
-74
| -0.3% | -$5.07K | 1.17% | 25 |
|
|
2019
Q2 | $1.83M | Sell |
25,206
-10
| -0% | -$786 | 1.12% | 27 |
|
|
2019
Q1 | $2.03M | Sell |
25,216
-49
| -0.2% | -$4.01K | 1.27% | 22 |
|
|
2018
Q4 | $2.33M | Sell |
25,265
-144
| -0.6% | -$12.7K | 1.64% | 16 |
|
|
2018
Q3 | $2.4M | Buy |
25,409
+218
| +0.9% | +$20.7K | 1.38% | 18 |
|
|
2018
Q2 | $2.33M | Sell |
25,191
-225
| -0.9% | -$22K | 1.42% | 16 |
|
|
2018
Q1 | $2.41M | Buy |
25,416
+27
| +0.1% | +$2.97K | 1.49% | 18 |
|
|
2017
Q4 | $2.46M | Sell |
25,389
-151
| -0.6% | -$14.2K | 1.5% | 17 |
|
|
2017
Q3 | $2.27M | Sell |
25,540
-324
| -1% | -$24.7K | 1.47% | 18 |
|
|
2017
Q2 | $1.88M | Buy |
25,864
+190
| +0.7% | +$12.8K | 1.25% | 20 |
|
|
2017
Q1 | $1.67M | Sell |
25,674
-2,204
| -8% | -$139K | 1.15% | 25 |
|
|
2016
Q4 | $1.75M | Sell |
27,878
-104
| -0.4% | -$6.35K | 1.22% | 21 |
|
|
2016
Q3 | $1.76M | Hold |
27,982
| – | – | 1.27% | 19 |
|
|
2016
Q2 | $1.73M | Sell |
27,982
-328
| -1% | -$20K | 1.31% | 21 |
|
|
2016
Q1 | $1.62M | Sell |
28,310
-520
| -2% | -$29K | 1.22% | 23 |
|
|
2015
Q4 | $1.71M | Sell |
28,830
-251
| -0.9% | -$14.5K | 1.29% | 21 |
|
|
2015
Q3 | $1.58M | Sell |
29,081
-1,895
| -6% | -$123K | 1.24% | 23 |
|
|
2015
Q2 | $2.08M | Sell |
30,976
-455
| -1% | -$29.7K | 1.46% | 18 |
|
|
2015
Q1 | $1.84M | Sell |
31,431
-1,338
| -4% | -$80.8K | 1.27% | 22 |
|
|
2014
Q4 | $2.14M | Sell |
32,769
-1,150
| -3% | -$72.5K | 1.43% | 19 |
|
|
2014
Q3 | $1.96M | Sell |
33,919
-1,054
| -3% | -$58.5K | 1.36% | 21 |
|
|
2014
Q2 | $1.97M | Sell |
34,973
-765
| -2% | -$40.1K | 1.34% | 23 |
|
|
2014
Q1 | $1.84M | Sell |
35,738
-245
| -0.7% | -$12.4K | 1.27% | 22 |
|
|
2013
Q4 | $1.9M | Sell |
35,983
-2,869
| -7% | -$141K | 1.32% | 23 |
|
|
2013
Q3 | $1.74M | Sell |
38,852
-137
| -0.4% | -$6.07K | 1.28% | 24 |
|
|
2013
Q2 | $1.61M | Buy |
+38,989
| New | +$1.71M | 0.99% | 32 |
|
Other funds holding ABBV
VCM
VPM
Roberts, Glore & Co's ABBV Position: Q1 2026 in Review
Roberts, Glore & Co reduced its AbbVie (ABBV) stake by 1% in Q1 2026, selling an estimated $68.8K and leaving 29,699 shares worth $6.46M. The position accounts for 1.77% of the portfolio, ranked #10.
Roberts, Glore & Co first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $18.9M in Q4 2021. 4,075 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.
- Roberts, Glore & Co held 29,699 shares of AbbVie worth $6.46M as of Q1 2026.
- Roberts, Glore & Co sold 310 AbbVie shares in Q1 2026, an estimated $68.8K.
- AbbVie made up 1.77% of Roberts, Glore & Co's portfolio in Q1 2026, its #10 holding.
- Roberts, Glore & Co first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
- Roberts, Glore & Co's AbbVie position peaked at $18.9M in Q4 2021.
- 4,075 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.
Based on Roberts, Glore & Co's 13F filing for Q1 2026, filed 4 May 2026.